KALBERMATTEN ADAM R 4/A

What Happened
Adam R. Kalbermatten, President and CEO of KORU Medical Systems, was granted 284,091 performance stock units (derivative award) on 2026-07-01. The award was reported at a $0.00 acquisition price (no cash paid). These are performance-based awards — 213,068 units may vest based on the company’s net sales growth on or prior to 12/31/2030, and 71,023 units may vest based on the company’s market capitalization at 12/31/2030. This filing is an amendment to the original report.

Key Details

• Transaction date: 2026-07-01; filing date (amended): 2026-07-13.
• Transaction code: A (award/acquisition, derivative); price reported: $0.00.
• Shares/units granted: 284,091 performance stock units (PSUs).
• Vesting terms (footnote): 213,068 tied to net sales growth; 71,023 tied to market-cap at 12/31/2030.
• Shares owned after transaction: Not disclosed in this filing.
• Amendment/remarks: This is an amended Form 4; filing includes a standard remark that the filing is not an admission of beneficial ownership. Power of Attorney previously filed.

Context
Performance stock units are contingent awards that only convert to actual shares if specified performance targets and timing conditions are met; they do not represent immediate market purchases or sales. Because the reported price is $0.00, this reflects a grant of contingent units rather than a paid acquisition. Note the filing was amended and appears later than the typical Section 16 reporting window (transaction 7/1/2026; amended filing 7/13/2026).